

We Claim:

1. A method of treating a patient suffering from thrombotic thrombocytopenic purpura (TTP) which comprises, 5 administering to said patient a pharmaceutically effective amount of protein C.

2. The method of Claim 1 wherein the protein C is human protein C zymogen.

10

3. The method of Claim 1 wherein the protein C is human activated protein C.

15 4. The method according to Claim 3, wherein the amount of human activated protein C is about 1  $\mu\text{g}/\text{kg}/\text{hr}$  to about 96  $\mu\text{g}/\text{kg}/\text{hr}$ .

20 5. The method of Claim 4, wherein the human activated protein C is administered by continuous infusion for about 1 to about 240 hours.

25 6. A method of treating thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of activated protein C such that an activated protein C plasma level of about 2 ng/ml to about 300 ng/ml is achieved.

30 7. The method of Claim 6 wherein the activated protein C is administered in a bolus injection.

8. The method of Claim 6 wherein the activated protein C is administered by continuous infusion for about 1 to about 240 hours.

5

9. The method of Claim 6 wherein the activated protein C is administered first as a bolus then as a continuous infusion.

10 10. The method of Claim 9 wherein one third of the activated protein C required to achieve activated protein C plasma levels in the range of about 2 ng/ml to about 300 ng/ml is administered in a bolus injection followed by continuous infusion of the remaining two thirds of the  
15 activated protein C.

11. A method of treating a patient suffering from hemolytic uremic syndrome (HUS) which comprises, administering to said patient a pharmaceutically effective  
20 amount of protein C.

12. The method of Claim 11 wherein the protein C is human protein C zymogen.

25 13. The method of Claim 11 wherein the protein C is human activated protein C.

14. The method according to Claim 13, wherein the amount of human activated protein C is about 1  $\mu\text{g}/\text{kg}/\text{hr}$  to  
30 about 96  $\mu\text{g}/\text{kg}/\text{hr}$ .

15. The method of Claim 14, wherein the human activated protein C is administered by continuous infusion for about 1 to about 240 hours.

5

16. A method of treating hemolytic uremic syndrome in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of activated protein C such that an activated protein C plasma level of about 2 ng/ml to about 300 ng/ml is achieved.

10

17. The method of Claim 16 wherein the activated protein C is administered in a bolus injection.

15

18. The method of Claim 16 wherein the activated protein C is administered by continuous infusion for about 1 to about 240 hours.

20

19. The method of Claim 16 wherein the activated protein C is administered first as a bolus then as a continuous infusion.

25

20. The method of Claim 19 wherein one third of the activated protein C required to achieve activated protein C plasma levels in the range of about 2 ng/ml to about 300 ng/ml is administered in a bolus injection followed by continuous infusion of the remaining two thirds of the activated protein C.